All In Biotech

Drug Trial Radar · NCT06527222

A Study of Ranolazine in ALS

Ranolazine in ALS: Safety, and Effect on Cramps, Function and Quality of Life.

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Apr 29, 2025

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Swathy Chandrashekhar, MBBSAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ALS Association
First posted
Jul 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • RanolazineDrug

    500mg twice daily

  • RanolazineDrug

    1000 mg twice daily

  • PlaceboDrug

    Ranolazine placebo twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Treatment-Emergent Adverse EventsTime frame: Up to 28 weeks
  2. Tolerability of treatment assignmentTime frame: Up to 28 weeks
  3. Muscle cramp frequencyTime frame: Up to 28 weeks
  4. Muscle cramp severityTime frame: Up to 28 weeks
  5. Muscle cramps impact on quality of lifeTime frame: Up to 28 weeks
  6. Safety Lab Cystatin CTime frame: Up to 28 weeks
  7. Safety Lab Estimated Glomerular Filtration Rate (eGFR)Time frame: Up to 28 weeks
  8. Safety Lab Alanine Transaminase (ALT)Time frame: Up to 28 weeks
  9. Safety Lab Aspartate Transferase (AST)Time frame: Up to 28 weeks
  10. Safety Lab Alkaline Phosphatase (ALP)Time frame: Up to 28 weeks
  11. Safety Lab Total BilirubinTime frame: Up to 28 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Mayo Clinic Florida

    Jacksonville, Florida · Recruiting

  • University of Kansas Medical Center

    Fairway, Kansas · Recruiting

  • University of Kansas Medical Center: Wichita

    Wichita, Kansas · Recruiting

  • University of Missouri Health Care

    Columbia, Missouri · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.